Hormonal
The LPAR1 antagonist EPGN2154, administered orally at 10 mg/kg, significantly reduces hepatic fibrosis and improves liver histology in preclinical NASH models, independent of body weight loss.
This research identifies a specific drug candidate (EPGN2154) that targets liver fibrosis directly through receptor antagonism, rather than just reducing body weight. While not yet available for humans, it highlights that treating NASH may require specific molecular interventions beyond just weight loss, particularly for fibrosis regression.
EPGN2154 demonstrated a hepato-protective effect independent of body weight loss in preclinical NASH models.
Why this rating
Preclinical animal models (mice), not human clinical trials.
Source
Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models
Jashdeep Bhattacharjee et al. · Hepatology Communications · 2023
DOI 10.1097/hc9.0000000000000323
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →